Price
No data yet.
Social Signal Score
Revenue
$425.49MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William H. Lewis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,664
- Beta
- 0.79
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 8.27
Financials
Revenue
$425.49M+4226.2%Net Income
$-13.24MEBITDA
$14.16MFree Cash Flow
$-95.09MEPS (diluted)
$-0.06Shares Outstanding (diluted)
217.35M+251.3%Operating Expenses
$457.50MCash & Debt
$1.16BRevenue by Segment (annual)
$606.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $606.42M | $-1.28B | $-6.41 |
| 2024 | $363.71M | $-913.77M | $-5.57 |
| 2023 | $305.21M | $-749.57M | $-5.34 |
| 2022 | $245.36M | $-481.53M | $-3.91 |
| 2021 | $188.46M | $-434.65M | $-3.88 |
| 2020 | $164.41M | $-294.09M | $-3.01 |
| 2019 | $136.47M | $-254.34M | $-3.01 |
| 2018 | $9.84M | $-324.28M | $-4.22 |
| 2017 | $0.00 | $-192.65M | $-2.89 |
| 2016 | $0.00 | $-176.27M | $-2.85 |
| 2015 | $0.00 | $-118.18M | $-2.02 |
| 2014 | $11.50M | $-79.16M | $-1.84 |
| 2013 | $11.50M | $-56.07M | $-1.60 |
| 2012 | $0.00 | $-41.37M | $-1.56 |
Valuation
INSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsprnewswire.com·5h ago·Positive
…s Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for n…
View source ↗
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $-0.37 per share
Typical surprise -12.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.06 vs $-0.67beat
- Thu, May 7$-0.76 vs $-0.96beat
- Thu, Feb 19$-1.54 vs $-1.07miss
- Thu, Oct 30$-1.75 vs $-1.33miss
- Thu, Aug 7$-1.70 vs $-1.30miss
- Thu, May 8$-1.42 vs $-1.34miss
Estimates and results for INSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INSM officers and directors.
- Bought
- —
- Sold
- $59.8m
0 trades
49 trades
- Sharoky Melvin Mdsold
- Adsett Rogersold
- Flammer Martina M.d.sold
- Flammer Martina M.d.sold
- Lewis Williamsold
- Lewis Williamsold
- Lewis Williamsold
- Lewis Williamsold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.